A Multiple Ascending Dose Study of Tadalafil to Assess the Pharmacokinetics and Safety in a Pediatric Population With Pulmonary Arterial Hypertension
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2017
At a glance
- Drugs Tadalafil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 16 Aug 2017 Planned End Date changed from 1 Sep 2019 to 1 May 2019.
- 16 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated